PDCD1 and plasma cell myeloma: Daratumumab targets not only CD38+ tumour cells, such as myeloma cells, but also normal CD38+ immunosuppressive B, T and myeloid cells and induces, like anti‐PD1/PD‐L1 therapy, an expansion of activated cytotoxic T cells.47, 48